UroGen Pharma Ltd. (URGN) Financials

URGN Assets vs Liabilities

DateAssetsLiabilities
2023-09-30 193.6 million 235.6 million
2023-06-30 95.4 million 233.8 million
2023-03-31 113.0 million 229.5 million
2022-12-31 136.2 million 225.0 million

URGN Free Cash Flow and Stock based compensation

Graph available only for supporters. Become a supporter to see it.
DateFree Cash FlowStock based compensation
2023-09-30 -17.4 million 2.2 million
2023-06-30 -20.3 million 2.2 million
2023-03-31 -25.8 million 2.3 million
2022-12-31 -21.8 million 2.4 million

URGN Net Income

No data available :(

URGN Cash and Debt

Graph available only for supporters. Become a supporter to see it.
DateCashDebtCapital Lease
2023-09-30 147.4 million - 1.0 million
2023-06-30 47.3 million - 1.2 million
2023-03-31 65.1 million 97.9 million 1.4 million
2022-12-31 100.0 million - 1.6 million

URGN Shares Outstanding

Graph available only for supporters. Become a supporter to see it.
DateShares Outstanding
2023-09-30 32.3 million
2023-06-30 23.5 million
2023-03-31 23.3 million
2022-12-31 23.1 million

URGN Expenses

Graph available only for supporters. Become a supporter to see it.
DateCapexR&DG&AS&M
2023-09-30 100000 10.2 million 21.8 million -
2023-06-30 15000 11.6 million 22.5 million -
2023-03-31 23000 12.5 million 24.5 million -
2022-12-31 13000 14.5 million 21.6 million -

URGN Cost of Revenue

Graph available only for supporters. Become a supporter to see it.
DateRevenueCost of Revenue
2023-09-30 20.9 million 2.4 million
2023-06-30 21.1 million 2.4 million
2023-03-31 17.2 million 2.3 million
2022-12-31 18.1 million 2.3 million

URGN

Price: $14.26

52 week price:
8.69
24.13

Earnings Per Share: -3.55 USD

P/E Ratio: -3.83

Exchange: NGM

Sector: Healthcare

Industry: Biotechnology

Volume: 20983

Ebitda: -286000

Market Capitalization: 452.1 million

Links: